Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01MFM
|
||||
| Former ID |
DNC012874
|
||||
| Drug Name |
H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C40H53N9O10
|
||||
| Canonical SMILES |
CC1=CC(=CC(=C1CC(C(=O)NC(CCCN=C(N)N[N+](=O)[O-])C(=O)NC<br />(CC2=CC=CC=C2)C(=O)NC(CCCCNC(=O)OCC3=CC=CC=C3)C(=O)O)N)<br />C)O
|
||||
| InChI |
1S/C40H53N9O10/c1-25-20-29(50)21-26(2)30(25)23-31(41)35(51)45-32(17-11-19-43-39(42)48-49(57)58)36(52)47-34(22-27-12-5-3-6-13-27)37(53)46-33(38(54)55)16-9-10-18-44-40(56)59-24-28-14-7-4-8-15-28/h3-8,12-15,20-21,31-34,50H,9-11,16-19,22-24,41H2,1-2H3,(H,44,56)(H,45,51)(H,46,53)(H,47,52)(H,54,55)(H3,42,43,48)/t31?,32-,33+,34+/m1/s1
|
||||
| InChIKey |
DTKHPEUFGZLWTF-OYKWTTPJSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Mu-type opioid receptor | Target Info | Inhibitor | [1] | |
| Delta-type opioid receptor | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | |||||
| Morphine addictionhsa04022:cGMP-PKG signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin releaseP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Enkephalin release | |||||
| Opioid proenkephalin pathway | |||||
| Opioid proopiomelanocortin pathway | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| Opioid Signalling | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | J Med Chem. 2005 Aug 25;48(17):5608-11.From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.